Recurrence of urothelial carcinoma of the bladder: A role for insulin-like growth factor-II loss of imprinting and cytoplasmic E-cadherin immunolocalization

Clinical Cancer Research

Volumn 14, Issue 21, 2008, Pages 6829-6838

  Gallagher, Emma M ^a   O'Shea, Deirdre M ^b   Fitzpatrick, Patricia ^a   Harrison, Michèle ^c   Gilmartin, Breege ^a   Watson, Jenny A ^a   Clarke, Trevor ^a   Leonard, Martin O ^a   McGoldrick, Aloysius ^a   Meehan, Maria ^a   Watson, Chanel ^d   Furlong, Fiona ^a   O'Kelly, Patrick ^b   Fitzpatrick, John M ^c   Dervan, Peter A ^c   O'Grady, Anthony ^b   Kay, Elaine W ^b   McCann, Amanda ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^d ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; SOMATOMEDIN B; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CARCINOMA; CANCER STAGING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYSTECTOMY; CYTOPLASM; EXON; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOCALIZATION; IN VITRO STUDY; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; UROGENITAL TRACT TUMOR; BLADDER TUMOR; DISEASE FREE SURVIVAL; GENETICS; GENOME IMPRINTING; IMMUNOHISTOCHEMISTRY; METABOLISM; TUMOR CELL LINE; TUMOR RECURRENCE;

CADHERINS; CELL LINE, TUMOR; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; GENOMIC IMPRINTING; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR II; MALE; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 58149242894     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0577     Document Type: Article

References (42)

1. Cui H. Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer. Disease Markers 2007;23:105-12.
2. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003;299:1753-5.
3. Woodson K, Flood A, Green L, et al. Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women. J Natl Cancer Inst 2004;96:407-10.
4. Sakatani T, Wei M, Katoh M, et al. Epigenetic heterogeneity at imprinted loci in normal populations. Biochem Biophys Res Commun 2001;283:1124-30.
5. Liu ZW, Zhou FJ, Luo YM, et al. Genomic imprinting of insulin-like growth factor II in prostate cancer and itsc linical significance. Ai Zheng 2006;25:765-70.
6. Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med 1998;4:1276-80.
7. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 2005;307:1976-8.
8. Moorehead RA, Sanchez OH, Baldwin RM, Khokha R. Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for humanlung adenocarcinoma. Oncogene 2003;22:853-7.
9. Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 1995;72:1189-93.
10. Kaneda A, Wang CJ, Cheong R, et al. Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci US A 2007;104:20926-31.
11. Knowles MA. Molecular subtypesof bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361-73.
12. 3 bladder cancer - indications for early cystectomy. Int Urol Nephrol 2003;36:41-4.
13. 1 grade 3 bladder tumours. Eur Urol 2007;51:161-7.
14. Elkin M, Shevelev A, Schulze E, et al. The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma. FEBS Lett 1995;374:57-61.
15. Rachmilewitz J, Elkin M, Looijenga LH, et al. Characterization of the imprinted IPW gene: allelic expression in normal and tumorigenic human tissues. Oncogene 1996;13:1687-92.
16. Oya M, Schulz WA. Decreased expression of p57 (KIP2) mRNA in human bladder cancer. Br J Cancer 2000;83:626-31.
17. Byun H-M, Wong H-L, Birnstein EA, Wolff EM, Liang G, Yang AS. Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res 2007;67:10753-8.
18. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47.
19. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, Larue L. IGF-II induces rapid β-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001;20:4942-50.
20. Manual for staging of cancer. American Joint Committee on Cancer (AJCC). 3rd ed. Philadelphia: JB Lippincott; 1998.
21. Mostofi F. Histological typing of urinary bladder tumours. In: International classification of tumours. Geneva: WHO; 1973.
22. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
23. Tadokoro K, Fujii H, Inoue T, Yamada M. Polymerase chain reaction (PCR) for detection of ApaI polymorphism at the insulin like growth factor II gene (IGF2). Nucleic Acids Res 1991;19:6967.
24. Gaunt TR, Cooper JA, Miller GJ, Day INM, O'Dell SD. Positive associations between single nucleotide polymorphisms in the IGF2 gene region and body mass index in adult males. Hum Mol Genet 2001;10:1491-501.
25. Monk D, Sanches R, Arnaud P, et al. Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human. Hum Mol Genet 2006;15:1259-69.
26. Pavelic K, Buković D, Pavelić J. The role of insulin-like growth factor 2 and its receptors in human tumors. Mol Med 2002;8:771-80.
27. Sasaki J, Konishi F, Kawamura YJ, Kai T, Takata O, Tsukamoto T. Clinicopathological characteristics of colorectal cancers with loss of imprinting of insulin-like growth factor 2. Int J Cancer 2006;119:80-3.
28. Zhang FR, He XB, Yang YH, Xie W. The expression and imprinting status of insulin-like growth factor 2 gene in colorectal cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003;20:31-4.
29. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
30. Lin YC, Wu MY, Li DR, Wu XY, Zheng RM. Prognostic and clinicopathological features of E-cadherin, α-catenin, β-catenin, γ-catenin and cyclin D1 expression in human esophageal squamous cell carcinoma. World J Gastroenterol 2004;10:3235-9.
31. Cooper MJ, Fischer M, Komitowski D, et al. Developmentally imprinted genes as markers for bladder tumor progression. J Urol 1996;155:2120-7.
32. Hoffmann MJ, Florl AR, Seifert HH, Schulz WA. Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer 2005;114:406-13.
33. Rochester MA, Patel N, Turney BW, et al. The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer. BJU Int 2007;100:1396-401.
34. Xie Q, Lin X, Zhang M, Han C, Guo Y. Expression of IGF-I and IGF-IR in bladder cancer. Ai Zheng 2004;23:707-9.
35. Iwamura M, Ishibe M, Sluss P, Cockett A. Characterization of insulin-like growth factor I binding sites in human bladder cancer cell lines. Urol Res 1993;21:27-32.
36. Aoki S, Yamada Y, Nakamura K, Taki T, Tobiume M, Honda N. Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer. Oncol Rep 2006;16:279-84.
37. Yin W, Chen N, Zhang Y, et al. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol 2006;19:1487-97.
38. Sitnikova L, Mendese G, Liu Q, et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 2008;14:1701-6.
39. Le TL, Yap AS, Stow JL. Recycling of E-cadherin: a potential mechanism for regulating cadherin dynamics. J Cell Biol 1999;146:219-32.
40. Mahnken A, Kausch I, Feller A, Kruger S. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder. Oncol Rep 2005;14:1065-70.
41. Wise TL, Pravtcheva DD. Delayed onset of Igf2-induced mammary tumors in Igf2r transgenic mice. Cancer Res 2006;66:1327-36.
42. Harper J, Burns JL, Foulstone EJ, Pignatelli M, Zaina S, Hassan AB. Soluble IGF2 receptor rescues ApcMin/+ intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res 2006;66:1940-8.